Company: WHWK
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001628280-25-015269
Chunk: 164

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1B
Chunk 164
---
 other income (expense), net3,767 6,168 Loss before income tax expense(63,691)(65,765)Income tax expense— — Net loss$(63,691)$(65,765)Other comprehensive loss:Unrealized (loss) income on available-for-sale debt securities(11)142 Comprehensive loss$(63,702)$(65,623)Net loss per share, basic and diluted$(2.36)$(2.44)Weighted average number of common shares outstanding, basic and diluted27,029,942 26,917,967 

The accompanying notes are an integral part of these consolidated financial statements. 

118

WHITEHAWK THERAPEUTICS, INC.

Consolidated Statements of Stockholders’ Equity

(in thousands, including share amounts) 

Stockholders’ EquityCommon StockAdditional Paid-In Capital Accumulated Other Comprehensive (Loss) IncomeAccumulated Deficit Total Stockholders' EquitySharesPar ValueBalance at December 31, 202224,435 $2 $361,689 $(115)$(203,198)$158,378 Issuance of common stock upon exercise of stock options42 — 78 — — 78 Share-based compensation expense— — 11,954 — — 11,954 Issuance of shares under the employee stock purchase plan77 — 408 — — 408 Unrealized gain on investments, net of tax— — — 142 — 142 Net loss— — — — (65,765)(65,765)Balance at December 31, 202324,554 $2 $374,129 $27 $(268,963)$105,195 Share-based compensation expense— — 10,839 — — 10,839 Issuance of common stock in conjunction with vesting of restricted stock units33 — — — — — Issuance of shares under the employee stock purchase plan94 — 146 — — 146 Unrealized loss on investments, net of tax— — — (11)— (11)Net loss— — — — (63,691)(63,691)Balance at December 31, 202424,681 $2 $385,114 $16 $(332,654